3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Neoplasms
4
Neoplasm Metastasis
3
Lung Neoplasms
2
Gastrointestinal Neoplasms
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Solid Tumors
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Rare Tumour
1
Rare Tumor
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Neoplasms by Site
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Genomic Instability
1
Interventions
Temozolomide
73
Bevacizumab
57
Radiotherapy
40
Radiosurgery
28
Carboplatin
23
Nivolumab
17
Etoposide
17
Cisplatin
17
pembrolizumab
16
Irinotecan
16
Ipilimumab
15
Magnetic Resonance Spectroscopy
14
Erlotinib Hydrochloride
14
Cyclophosphamide
14
Carmustine
14
Pemetrexed
13
Topotecan
10
Surgical Procedures, Operative
10
Capecitabine
10
Lapatinib
9
Filgrastim
9
Trastuzumab
8
Thalidomide
8
Sunitinib
8
Paclitaxel
8
Lomustine
8
Aminolevulinic Acid
8
encorafenib
7
binimetinib
7
Vincristine
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Brain Neoplasms
×
alectinib
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts